Starting Biologic Therapy for HS in Adolescent Patients

In "Starting Biologic Therapy for HS in Adolescent Patients," our experts turn to the timing and framing of biologic therapy in teenagers preparing for major life transitions.

The panel discusses how milestones like leaving for college often prompt adolescents to seek more aggressive treatment, wanting their disease under control before facing a new environment without the comfort of home. With two biologics now indicated down into the adolescent population, panelists describe this as a meaningful expansion of options at exactly the moment patients are most motivated to act.

Asked about parental pushback, the group agrees that injectable therapy can sound alarming to families who imagine significant side effects. Their response is to reassure parents that current biologics carry a well-established safety profile, monitored over many years without new safety signals, while also setting realistic expectations that clearing disease takes time rather than happening after a single dose. One panelist describes deliberately planting the idea of biologic therapy at a first visit, then bringing the patient back in two to four weeks once the family has had time to process the recommendation, discuss it at home, and arrive at a decision they feel ownership over rather than pressure into.

Several strategies recur: reminding families that therapy isn't permanent and can be stopped if it isn't the right fit, which panelists find lowers resistance to starting; and making sure parents fully grasp how much the disease is affecting their child's daily life, since some details, like hiding symptoms from friends, may not have been shared at home. The panel agrees on encouraging patients to begin treatment at the time of diagnosis when possible, acknowledging that required baseline lab work, particularly before adalimumab, can still delay a same-day start by several days.

The next episode in this series, "Choosing First-Line Biologics and Follow-Up Strategies for HS," has the panel comparing how newer IL-17 inhibitors are reshaping first-line biologic selection.